First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve

被引:154
|
作者
Rodriguez-Grunert, Leonardo [1 ]
Neto, Manoel Passos Galvao [2 ]
Alamo, Munir [1 ]
Ramos, Almino Cardoso [2 ]
Baez, Percy Brante [1 ]
Tarnoff, Michael [3 ]
机构
[1] Hosp Dipreca, Ctr Cirugia Obesidad, Santiago, Chile
[2] Gastro Obeso Ctr, Sao Paulo, Brazil
[3] Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA
关键词
Bariatric; Endoluminal; Diabetes; Obesity; Duodenum;
D O I
10.1016/j.soard.2007.07.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital. Methods: The DJBS is a 60-cm sleeve anchored in the duodenum to create a duodenal-jejunal bypass. In a 12-patient prospective, open-label, single-center, 12-week study, the device was endoscopically implanted, left in situ, and retrieved. The study included 5 men and 7 women, with a mean body mass index of 43 kg/m(2). Of the 12 patients, 4 had type 2 diabetes. The primary endpoints were the incidence and severity of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in co-morbid status. Results: The DJBS was endoscopically delivered and retrieved in all patients (mean implant/explant time of 26.6 and 43.3 min, respectively). Of the 12 patients, 10 were able to maintain the device for 12 weeks and 2 underwent explantation after 9 days secondary to poor device placement. Several self-limited adverse events were possibly or definitely related to the device, including 6 episodes of abdominal pain, 18 of nausea, and 16 of vomiting, mainly within 2 weeks of implantation. Two partial pharyngeal tears occurred during explantation. Implant site inflammation was encountered in all patients. No device-related event was considered severe. The average percentage of excess weight loss for the 10 patients with the device in place for 12 weeks was 23.6%, with all patients achieving at least 10% excess weight loss. All 4 diabetic patients had normal fasting plasma glucose levels without hypoglycemic medication for the entire 12 weeks. Of these 4 patients, 3 had decreased hemoglobin A(1C) of >=.5% by week 12. Conclusion: The DJBS can be safely delivered and removed endoscopically and left in situ for 12 weeks. The device had a favorable safety and encouraging efficacy profile. Randomized prospective trials are warranted. (Surg Obes Relat Dis 2008;4:55-59.) (C) 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [21] Endoscopic Management of Anchor Erosion Adjacent to the Pylorus Following Duodenal-Jejunal Bypass Sleeve
    Hourneaux De Moura, Eduardo Guimaraes
    Hourneaux de Moura, Diogo Turiani
    Galvao-Neto, Manoel
    Sakai, Christiano Makoto
    Rodela Silva, Gustavo Luis
    Bazarbashi, Ahmad Najdat
    Thompson, Christopher C.
    OBESITY SURGERY, 2019, 29 (06) : 2003 - 2004
  • [22] Comment on: Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity
    Brethauer, Stacy A.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2010, 6 (02) : 131 - 131
  • [23] Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie, P.
    Betzel, B.
    Aarts, E. O.
    Janssen, I. M. C.
    Wahab, P.
    Berends, F. J.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2015, 11 (05) : 1099 - 1104
  • [24] Mini-Duodenal Switch: Single Anastomosis Duodenal-Jejunal Bypass with Sleeve Gastrectomy: a Novel Metabolic Surgery
    Lee, W.
    Chen, J.
    Ser, K.
    Tsou, J.
    Lee, Y.
    OBESITY SURGERY, 2013, 23 (08) : 1067 - 1067
  • [25] Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity
    Betzel, Bark
    Koehestanie, Parviez
    Aarts, Edo O.
    Dogan, Kemal
    Homan, Jens
    Janssen, Ignace M. C.
    Wahab, Peter J.
    Groenen, Marcel J. M.
    Berends, Frits J.
    GASTROINTESTINAL ENDOSCOPY, 2015, 82 (05) : 845 - 852
  • [26] COMPARISON OF EFFECTS OF SLEEVE GASTRECTOMY, DUODENAL-JEJUNAL BYPASS AND ILEAL TRANSPOSITION FOR TYPE II DIABETES
    Tong, D.
    Lai, K. K.
    Lee, N.
    Can, K. T.
    Law, S.
    OBESITY SURGERY, 2014, 24 (08) : 1149 - 1149
  • [27] Induction of Meal-related Symptoms as a Novel Mechanism of Action of the Duodenal-Jejunal Bypass Sleeve
    McMaster, Jessica J.
    Rich, Graeme G.
    Shanahan, Erin R.
    Do, Anh T.
    Fletcher, Linda M.
    Kutyla, Marguerite J.
    Tallis, Caroline
    Jones, Mike P.
    Talley, Nicholas J.
    Macdonald, Graeme A.
    Chachay, Veronique S.
    Holtmann, Gerald J.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2020, 54 (06) : 528 - 535
  • [28] Duodenal Crohn's disease - gastro-jejunal bypass versus duodenal-jejunal bypass - a video vignette
    Elorza-Echaniz, G.
    Aguirre-Allende, I.
    Borda-Arrizabalaga, N.
    Eizaguirre-Letamendia, E.
    Enriquez-Navascues, J. M.
    COLORECTAL DISEASE, 2020, 22 (11) : 1788 - 1788
  • [29] Duodenal-jejunal bypass changes the composition of the gut microbiota
    Kashihara, Hideya
    Shimada, Mitsuo
    Yoshikawa, Kozo
    Higashijima, Jun
    Nakao, Toshihiro
    Nishi, Masaaki
    Takasu, Chie
    SURGERY TODAY, 2017, 47 (01) : 137 - 140
  • [30] FREQUENCY AND MANAGEMENT OF COMPLICATIONS OF THE DUODENAL-JEJUNAL BYPASS LINER
    Betzel, B.
    Koehestanie, P.
    Homan, J.
    Dogan, K.
    Aarts, E.
    Wahab, P.
    Groenen, M.
    Janssen, I.
    Berends, F.
    OBESITY SURGERY, 2014, 24 (08) : 1163 - 1163